 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LASN01 / Lassen Therap
Trial completion date: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (clinicaltrials.gov) - Jan 4, 2025
P2, N=41, Active, not recruiting, Sponsor: Lassen Therapeutics Inc.
Trial completion date: Oct 2025 --> Jan 2026
- | LASN01 / Lassen Therap
Enrollment closed: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (clinicaltrials.gov) - Oct 8, 2024
P2, N=41, Active, not recruiting, Sponsor: Lassen Therapeutics Inc.
Trial completion date: Oct 2025 --> Jan 2026 Recruiting --> Active, not recruiting
- || LASN01 / Lassen Therap
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (clinicaltrials.gov) - Aug 14, 2024
P1/2, N=75, Active, not recruiting, Sponsor: Lassen Therapeutics 1 PTY LTD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Feb 2025 | Trial primary completion date: Sep 2025 --> Feb 2025
- | LASN01 / Lassen Therap
Trial completion date: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (clinicaltrials.gov) - May 29, 2024
P2, N=36, Recruiting, Sponsor: Lassen Therapeutics Inc.
Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Feb 2025 | Trial primary completion date: Sep 2025 --> Feb 2025 Trial completion date: Mar 2025 --> Sep 2025
- || LASN01 / Lassen Therap
Phase classification, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (clinicaltrials.gov) - Apr 28, 2024
P1/2, N=90, Recruiting, Sponsor: Lassen Therapeutics 1 PTY LTD
Trial completion date: Mar 2025 --> Sep 2025 Phase classification: P1 --> P1/2 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- ||| LASN01 / Lassen Therap
Enrollment change: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (clinicaltrials.gov) - Apr 4, 2024
P2, N=36, Recruiting, Sponsor: Lassen Therapeutics Inc.
Phase classification: P1 --> P1/2 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 N=24 --> 36
- || LASN01 / Lassen Therap
New P2 trial: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (clinicaltrials.gov) - Jan 25, 2024
P2, N=24, Recruiting, Sponsor: Lassen Therapeutics Inc.
- LASN01 - Lassen Therap, Cedars / Sinai
LASN01, A HIGH AFFINITY ANTI?INTERLEUKIN?11 RECEPTOR ANTIBODY, BLOCKS PATHOLOGICAL MECHANISMS OF THYROID EYE DISEASE LINKED TO CLINICAL EFFICACY () - Sep 20, 2023 - Abstract #ATA2023ATA_672;
LASN01 is a potent inhibitor of IL?11 signaling, leading to the suppression of cell proliferation and HA secretion from TED OF, while also demonstrating anti?fibrotic activity. For this reason, LASN01 is worthy of further investigation as a potential new therapeutic agent for the treatment of TED.
- || LASN01 / Lassen Therap
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (clinicaltrials.gov) - Jul 5, 2023
P1, N=80, Recruiting, Sponsor: Lassen Therapeutics 1 PTY LTD
For this reason, LASN01 is worthy of further investigation as a potential new therapeutic agent for the treatment of TED. Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
- LASN01 - Lassen Therap, Cedars / Sinai
A Novel Interleukin-11 Receptor Antibody, LASN01 Is Well Tolerated and Demonstrates Target Engagement in Phase 1 (Red 1+2) - Jun 17, 2023 - Abstract #ERS2023ERS_2527;
Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024 Physiology; Cell and molecular biology; General respiratory patient care
- LASN01 - Lassen Therap, Cedars / Sinai
A First-in-Class IL-11 Receptor Blocking Antibody as a Treatment for Pulmonary Fibrosis (Walter E. Washington Convention Center, Room 146 A-C (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_4333;
blockade and support the continued clinical advancement of LASN01, a human anti-IL-11R? as a first-in-class treatment for IPF, other forms of interstitial lung disease, and potentially additional immune-fibrotic diseases.
- || LASN01 / Lassen Therap
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (clinicaltrials.gov) - Feb 10, 2023
P1, N=64, Recruiting, Sponsor: Lassen Therapeutics 1 PTY LTD
as a first-in-class treatment for IPF, other forms of interstitial lung disease, and potentially additional immune-fibrotic diseases. Trial completion date: May 2024 --> Dec 2023 | Trial primary completion date: May 2024 --> Dec 2023
- ||| LASN01 / Lassen Therap
Enrollment open: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (clinicaltrials.gov) - Aug 1, 2022
P1, N=64, Recruiting, Sponsor: Lassen Therapeutics 1, Inc.
Trial completion date: May 2024 --> Dec 2023 | Trial primary completion date: May 2024 --> Dec 2023 Not yet recruiting --> Recruiting
- | LASN01 / Lassen Therap
New P1 trial: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (clinicaltrials.gov) - Apr 14, 2022
P1, N=64, Not yet recruiting, Sponsor: Lassen Therapeutics 1, Inc.
- LASN01 - Lassen Therap, Cedars / Sinai
Characterization of a Novel IL-11 Receptor-Blocking Antibody, a Potential Therapeutic for IPF and Other Fibrosing Lung Diseases (Room 215-216 (South Building, Level 2), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_3959;
Rationale: Interleukin 11 (IL-11) is a pleiotropic cytokine that is reported to be an important regulator of fibroblast activation and tissue fibrosis. Combined, these data indicate that IL-11 is a prominent fibroinflammatory mediator in the lung and IL-11RA blockade may provide a novel therapeutic approach to treat grievous diseases such as IPF or other fibrosing ILD’s.